Impact of a pharmacy-initiated HIV admission note on medication errors within an academic hospital

Hospital Pharmacy

Volumn 40, Issue 10, 2005, Pages 874-881

  Sterling, Emily S ^a   Romanelli, Frank ^b   Martin, Craig A ^b,c   Hoven, Ardis D ^d   Smith, Kelly M ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d University of Kentucky College of Medicine ^*

Author keywords

HIV admission note; Medication errors; Pharmacy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

DRUG HYPERSENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HOSPITAL PHARMACY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL EDUCATION; MEDICATION ERROR; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 27644451734     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870504001006     Document Type: Review

References (18)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. 1998;338:853-860.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potential antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280:1497-1503.
3. AIDSinfo. Guidelines for the use of antiretrovirals in HIV-1-infected adults and adolescents, April 7, 2005. Available at: http://aidsinfo.nih.gov/ guidelines/default_db2.asp?id=50. Accessed on September 4, 2005.
4. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Eng J Med. 1997;336:1531-1532.
5. De Maat M, Post TM, Jonker DM, et al. Pharmacotherapy of hospitalized HIV-infected patients in a general hospital during 1990, 1997, and 2001. Clin Drug Invest. 2003;23:45-53.
6. Paragon JJ, Lesar TS. Update on prescribing errors with HAART. AIDS Read. 2003;13:268-278.
7. National Coordinating Council on Medication Error Reporting and Prevention. Available at: http://www.nccmerp. org/. Accessed on June 4, 2004.
8. Edelstein H, Wilson M. Antiretroviral medication errors were universal in hospitalized HIV-seropositive patients at a teaching hospital. J Acquir Immune Defic Syndr. 2001;28:496.
9. Segarra-Newnham M. Preventing medication errors with a "pharmacy admission note" for HIV-positive patients. Hosp Pharm. 2002;37:34-37.
10. Geletko S, Small FJ, Pinon M. Using a pharmacist's progress-note form to manage HIV pharmacotherapy. Am J Health Syst Pharm. 1999;56:420-421.
11. Bozek PS, Perdue BE, Bar-Din M, Weidle PJ. Effect of pharmacist interventions on medication use and cost in hospitalized patients with or without HIV infection. Am J Health Syst Pharm. 1998;55:1151-1155.
12. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA. 1995;274:35-43.
13. Purdy BD, Raymond AM, Lesar TS. Antiretroviral prescribing errors in hospitalized patients. Ann Pharmacother. 2000;34:833-838.
14. Valenti WM. The HIV specialist improves quality of care and outcomes. AIDS Read. 2002;12:202-205.
15. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185:S143-S1451.
16. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29:S2-S10.
17. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
18. American Society of Health-System Pharmacist 2015 Initiatives. Available at: http://www.ashp.org/2015/. Accessed on April 18, 2005.